Can RAPAFLO work in patients with larger prostates?
Prostate size does not necessarily correlate with the severity of BPH symptoms. In RAPAFLO’s clinical trials, the baseline IPSS scores were 21.2 and 21.5. In fact, in patients who’s baseline was ≥ 20 the IPSS reductions were even greater than those seen in the overall study population (-7.8 vs -6.4).